How Artificial Intelligence is Halving Regulatory Workflows in High-Stakes Industries
New York, Tuesday, 29 September 2026.
Akkodis and Biolevate partnered to deploy tailored artificial intelligence across heavy industries, cutting clinical report times in half using traceable data rather than standard conversational tools.
Strategic Alliance Announcement and Timeline
Akkodis, a global tech services leader and subsidiary of the Adecco Group, has formally partnered with Biolevate to deploy artificial intelligence-driven platforms aimed at accelerating scientific, regulatory, and technical documentation [1][2]. The strategic partnership was announced on 28 September 2026 according to some reports, while others cite 29 September 2026, marking a significant move to address structural compliance bottlenecks in heavily regulated sectors [2][4]. This collaboration targets executive leaders seeking a pathway to significantly enhance operational productivity while maintaining strict oversight through governed AI workflows [1].
Technology Integration and Platform Capabilities
The collaboration leverages Biolevate’s AI platform, ELISE, which utilizes natural language processing, computer vision, and graph-based AI models to manage knowledge workflows [1][2]. Unlike general conversational AI, the platform is specifically designed for controlled sources and traceable evidence to ensure transparency and expert oversight [2][4]. Akkodis contributes consulting, engineering, and regulatory expertise to integrate these tools into existing client frameworks across more than 30 countries [2].
Measurable Productivity Improvements
Biolevate claims performance metrics for AI-assisted workflows indicate scientific literature reviews can be completed up to 2.5 times faster using the integrated system [1][4]. Clinical study report generation and regulatory dossier preparation time are reported to be reduced by up to 50 percent, while MedTech development workflows are accelerated by up to 30 percent [2][4]. These efficiency gains are calculated based on internal performance data regarding workflow acceleration and time reduction [1][2].
Deployment Strategy and Market Expansion
The partnership intends to expand from the initial launch markets of France and Belgium to additional, unspecified global markets [1][2]. While the initial launch is confirmed for late September 2026, there is no specific deadline provided in the text for the global expansion phase [alert! ‘No specific deadline provided in text’] [4]. The rollout focuses on scaling AI-enabled documentation processes in regulated environments systematically [2].
Targeted Industries and Governance
The collaboration targets heavily regulated sectors including life sciences, aerospace, defense, and energy [1][4]. High-value workflows include scientific writing, regulatory documentation, validation engineering, and medical device development lifecycle management [2]. This focus ensures that organizations in highly regulated industries utilize governed workflows that support expert decision-making rather than relying solely on powerful AI models [1][4].
Executive Perspectives on Operational Impact
Jo Debecker, President and CEO of Akkodis, stated that the partnership reflects the core of Akkodis Intelligence by combining advanced AI with deep human expertise [2][4]. Joël Belafa, Co-founder and CEO of Biolevate, noted that partnering with Akkodis enables teams to redefine how they work in the AI era, boosting productivity and safeguarding critical knowledge [1][2]. Both executives emphasized the necessity of scalable, traceable solutions aligned with regulatory requirements [1][4].
Organizational Context and Background
Akkodis operates globally with 40,000 engineers across more than 30 countries and is headquartered in Switzerland as part of the Adecco Group [2][4]. Biolevate is an AI-native technology company backed by investors including EQT Ventures and Orange Ventures, serving pharmaceutical clients such as Sanofi and Merck/MSD [2][4]. The partnership aims to modernize documentation processes following Akkodis’s previous expansion into life sciences consulting through the acquisition of Raland Compliance Partners announced on 23 January 2025 [3].